论文部分内容阅读
AIM:To compare the efficacy of the proton-pump inhibitor,rabeprazole,with that of the H 2-receptor antagonist,ranitidine,as on-demand therapy for relieving symptoms associated with non-erosive reflux disease(NERD).METHODS:This is a single center,prospective,randomized,open-label trial of on-demand therapy with rabeprazole(group A) vs ranitidine(group B) for 4 wk.Eighty-three patients who presented to the American University of Beirut Medical Center with persistent gastroesophageal reflux disease(GERD) symptoms and a normal upper gastrointestinal endoscopy were eligible for the study.Patients in group A(n = 44) were allowed a maximum rabeprazole dose of 20 mg twice daily,while those in group B(n = 39) were allowed a maximum ranitidine dose of 300 mg twice daily.Efficacy was assessed by patient evaluation of global symptom relief,scores of the SF-36 quality of life(QoL) questionnaires,total number of pills used,and number of medication-free days.RESULTS:Among the 83 patients who were enrolled in the study,76 patients(40 in the rabeprazole group and 36 in the ranitidine group) completed the 4-wk trial.Baseline characteristics were comparable between both groups.After 4 wk,there was no significant difference in the subjective global symptom relief between the rabeprazole and the ranitidine groups(71.4% vs 65.4%,respectively;P = 0.9).There were no statistically significant differences between mean cumulative scores of the SF-36 QoL questionnaire for the two study groups(rabeprazole 22.40 ± 27.53 vs ranitidine 17.28 ± 37.06;P = 0.582).There was no significant difference in the mean number of pills used(rabeprazole 35.70 ± 29.75 vs ranitidine 32.86 ± 26.98;P = 0.66).There was also no statistically significant difference in the mean number of medication-free days between both groups.CONCLUSION:Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD.Both medications were associated with improved quality of life.
AIM: To compare the efficacy of the proton-pump inhibitor, rabeprazole, with that of the H 2 -receptor antagonist, ranitidine, as on-demand therapy for relieving symptoms associated with non-erosive reflux disease (NERD) .METHODS: This is a single center, prospective, randomized, open-label trial of on-demand therapy with rabeprazole (group A) vs ranitidine (group B) for 4 wk. Light-three patients who presented to the American University of Beirut Medical Center with persistent gastroesophageal Reflux disease (GERD) symptoms and a normal upper gastrointestinal endoscopy were eligible for the study. Patients in group A (n = 44) were allowed a maximum rabeprazole dose of 20 mg twice daily, while those in group B (n = 39) were allowed a maximum ranitidine dose of 300 mg twice daily. Efficacy was assessed by patient evaluation of global symptom relief, scores of the SF-36 quality of life (QoL) questionnaires, total number of pills used, and number of pills-free-days. RESULTS: Among the 83 patients who were enr olled in the study, 76 patients (40 in the rabeprazole group and 36 in the ranitidine group) completed the 4-wk trial. Baseline characteristics were comparable between both groups. After 4 wk, there was no significant difference in the subjective global symptom relief Between the rabeprazole and the ranitidine groups (71.4% vs 65.4%, respectively; P = 0.9). There were no statistically significant differences between the mean cumulative scores of the SF-36 QoL questionnaire for the two study groups (rabeprazole 22.40 ± 27.53 vs ranitidine 17.28 ± 37.06; P = 0.582). There was no significant difference in the mean number of pills used (rabeprazole 35.70 ± 29.75 vs ranitidine 32.86 ± 26.98; P = 0.66). There was no significant difference in the mean number of medication -free days between both groups. CONCLUSION: Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD.Both medications were associated with improved quality of life.